Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.88
- Piotroski Score 3.00
- Grade Overweight
- Symbol (CAPR)
- Company Capricor Therapeutics, Inc.
- Price $18.61
- Changes Percentage (4.61%)
- Change $0.82
- Day Low $17.51
- Day High $18.88
- Year High $23.40
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $37.50
- High Stock Price Target $43.00
- Low Stock Price Target $25.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.83
- Trailing P/E Ratio -6.31
- Forward P/E Ratio -6.31
- P/E Growth -6.31
- Net Income $-22,287,542
Income Statement
Quarterly
Annual
Latest News of CAPR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
With 52% ownership, Capral Limited (ASX:CAA) boasts of strong institutional backing
Analyzing ownership and past performance data can reveal stock opportunities. Institutional investors hold a 52% stake in Capral Limited (ASX:CAA), indicating potential upside or downside. Monitoring ...
By Yahoo! Finance | 1 day ago -
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?
A list of top multibagger stocks for 2025 includes Capricor Therapeutics, Inc. November saw market highs after Fed rate cut and Trump's win. Fed Chair Powell anticipates steady inflation and fewer rat...
By Yahoo! Finance | 6 days ago -
Fox News Entertainment Newsletter: James Van Der Beek missed cancer symptoms, Leonardo DiCaprio's party upset
James Van Der Beek, revealing his cancer diagnosis, initially mistook symptoms. Leonardo DiCaprio's lavish birthday angered neighbors. Ben Affleck warns of cancel culture in Hollywood. Amy Adams rejec...
By Fox News | 1 week ago
